Cardiovascular Disease in Patients with Schizophrenia
Schizophrenia is a chronic, heterogeneous neuropsychiatric illness that is among the world’s top 20 causes of long term disability.
This module provides an evidence-based overview of national and international data on the prevalence and risk factors for cardiovascular disease (CVD), the contributory effects of antipsychotic drugs to cardiovascular risk, and the potential cardiotoxicity associated with clozapine treatment.
It presents local experiences with a shared model of care and discusses the potential of such models to reduce the cardiovascular risk burden in patients with schizophrenia.
Medical Journal of Australia
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Nurse / Midwife, Researcher, Retired, Specialist - Other, Specialist General Practitioner
- CSANZ Virtual 2020
- Posted By The Cardiac Society of Australia and New Zealand (CSANZ)
- Posted Date: 2020-11-24
- Opportunity to review hundreds of scientific abstracts highlighting updates on the most critical top
- What works and what doesn't in smoking cessation. ...
- Posted By In Vivo Academy
- Posted Date: 2020-11-22
- Location:Online webinar
- What REALLY helps patients quit smoking?
- Haemochromatosis: Preventing harm caused by iron o...
- Posted By ThinkGP
- Posted Date: 2020-10-14
- Haemochromatosis is the most common genetic disorder in Caucasian people of northern European
- Diagnostic Imaging Accreditation Scheme (DIAS) Sta...
- Posted By AGPAL & QIP Education and Training
- Posted Date: 2020-10-10
- Strengthen areas to reduce risk and provide strategies to improve patient and equipment safety.